163 related articles for article (PubMed ID: 36788079)
1. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas.
Han LM; Lee KW; Uludag G; Seider MI; Afshar AR; Bloomer MM; Pekmezci M
Mod Pathol; 2023 Apr; 36(4):100081. PubMed ID: 36788079
[TBL] [Abstract][Full Text] [Related]
2. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW
Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176
[TBL] [Abstract][Full Text] [Related]
3. BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma.
Shah AA; Bourne TD; Murali R
Pathology; 2013 Dec; 45(7):651-6. PubMed ID: 24247622
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients.
Kumar N; Singh MK; Singh L; Lomi N; Meel R; Pushker N; Sen S; Kashyap S
Hum Cell; 2023 Jan; 36(1):342-352. PubMed ID: 36282437
[TBL] [Abstract][Full Text] [Related]
5. Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.
Szalai E; Wells JR; Ward L; Grossniklaus HE
Ophthalmology; 2018 Feb; 125(2):203-209. PubMed ID: 28823399
[TBL] [Abstract][Full Text] [Related]
6. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
[TBL] [Abstract][Full Text] [Related]
7. Ki67 is a better marker than PRAME in risk stratification of BAP1-positive and BAP1-loss uveal melanomas.
Donizy P; Spytek M; Krzyziński M; Kotowski K; Markiewicz A; Romanowska-Dixon B; Biecek P; Hoang MP
Br J Ophthalmol; 2023 Sep; ():. PubMed ID: 37734766
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.
Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA
Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622
[TBL] [Abstract][Full Text] [Related]
9. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma.
Koopmans AE; Verdijk RM; Brouwer RW; van den Bosch TP; van den Berg MM; Vaarwater J; Kockx CE; Paridaens D; Naus NC; Nellist M; van IJcken WF; Kiliç E; de Klein A
Mod Pathol; 2014 Oct; 27(10):1321-30. PubMed ID: 24633195
[TBL] [Abstract][Full Text] [Related]
13. Genomic Profiling of Metastatic Uveal Melanoma Shows Frequent Coexisting BAP1 or SF3B1 and GNAQ/GNA11 Mutations and Correlation With Prognosis.
Isaacson AL; Sompallae RR; Guseva NV; Bellizzi AM; Bossler AD; Ma D
Am J Clin Pathol; 2022 Aug; 158(2):177-186. PubMed ID: 35212356
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
[TBL] [Abstract][Full Text] [Related]
16. Comparing the Prognostic Value of BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 Immunohistochemistry in Uveal Melanoma.
van de Nes JA; Nelles J; Kreis S; Metz CH; Hager T; Lohmann DR; Zeschnigk M
Am J Surg Pathol; 2016 Jun; 40(6):796-805. PubMed ID: 27015033
[TBL] [Abstract][Full Text] [Related]
17. Piloting a Deep Learning Model for Predicting Nuclear BAP1 Immunohistochemical Expression of Uveal Melanoma from Hematoxylin-and-Eosin Sections.
Zhang H; Kalirai H; Acha-Sagredo A; Yang X; Zheng Y; Coupland SE
Transl Vis Sci Technol; 2020 Sep; 9(2):50. PubMed ID: 32953248
[TBL] [Abstract][Full Text] [Related]
18. BAP1 germline mutation in two first grade family members with uveal melanoma.
Maerker DA; Zeschnigk M; Nelles J; Lohmann DR; Worm K; Bosserhoff AK; Krupar R; Jägle H
Br J Ophthalmol; 2014 Feb; 98(2):224-7. PubMed ID: 24187051
[TBL] [Abstract][Full Text] [Related]
19. BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas.
Field MG; Kuznetsov JN; Bussies PL; Cai LZ; Alawa KA; Decatur CL; Kurtenbach S; Harbour JW
Clin Cancer Res; 2019 Sep; 25(18):5663-5673. PubMed ID: 31285370
[TBL] [Abstract][Full Text] [Related]
20. Basal cell carcinomas developing independently from BAP1-tumor predisposition syndrome in a patient with bilateral uveal melanoma: Diagnostic challenges to identify patients with BAP1-TPDS.
Melzer C; Sharma A; Peters S; Aretz S; Biswas A; Holz FG; Loeffler KU; Herwig-Carl MC
Genes Chromosomes Cancer; 2019 Jun; 58(6):357-364. PubMed ID: 30578689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
